Annotation Detail

Information
Associated Genes
PIK3CA
Associated Variants
PIK3CA MUTATION
PIK3CA MUTATION
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1705
Gene URL
https://civic.genome.wustl.edu/links/genes/37
Variant URL
https://civic.genome.wustl.edu/links/variants/311
Rating
1
Evidence Type
Predictive
Disease
Colorectal Cancer
Evidence Direction
Supports
Drug
Cetuximab
Evidence Level
D
Clinical Significance
Resistance
Pubmed
22586653
Drugs
Drug NameSensitivitySupported
CetuximabResitance or Non-Reponsetrue